ARTHUR-D.-LITTLE
Arthur D. Little (ADL) today announced the promotion of nine of its consultants to the rank of Partner across a number of its global offices.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220315005634/en/
Each new Partner has demonstrated their commitment to ADL, passion and dedication to the industries and clients they serve, and best-in-class experience and expertise. ADL credits a lot of its ongoing growth and success to the development, promotion and retention of its internal talent, with a recent survey on Vault acknowledging these values for setting ADL apart as an employer.
The latest promotions to Partner are as follows:
- Ryan Alnesayan, Partner, Public Services Practice, Riyadh. Leading ADL Riyadh’s office, Ryan has over 14 years of consulting and business advisory experience in strategic planning, economic development, and large-scale transformation projects, with a focus on Saudi Arabia.
- Marcus Beard, Partner, Risk Practice, Cambridge. Marcus’ area of expertise is risk management, in which he primarily focuses on developing next-generation risk management approaches, culture assessment, safety and risk governance and assurance, risk analysis, and executive leadership training, with deep industry experience in travel & transportation.
- Dr. Engin Beken, Partner, Operations Management Practice, Frankfurt & Vienna. Engin is a key expert in strategic performance improvement and digitalization. He is a strong contributor to ADL’s global operations management practice and works with our clients globally, especially in asset-heavy industries.
- Florence Carlot, Partner, Energy & Utilities Practice, Brussels. Florence focuses on strategy and organization in the energy & utilities industry. She has been working within the European energy and utilities sector for over 15 years, enabling large operational and strategic change initiatives across the energy value chain.
- Julien Duvaud-Schelnast, Partner, Telecommunications, Information Technology, Media & Electronics (TIME) Practice, Paris & Stockholm. Operating in both France and Sweden, Julien is an expert on trending topics within the TIME practice, including infrastructure, private networks and sustainability.
- Dr. Michael Eiden, Partner, Technology & Innovation Practice, London. Michael is the Global Head of Artificial Intelligence and Machine Learning at ADL. He is an industry expert with more than 20 years of hands-on experience in designing, developing and commercializing AI solutions in different industries.
- Ben Enejo, Partner, Healthcare & Life Sciences Practice, Boston. Ben is an experienced management consultant and industry expert, having worked with various global biopharmaceutical companies on strategies to accelerate the development of new medicines through to commercialization. Particular areas of expertise include clinical trial acceleration; R&D transformation, including advanced technology application, increasing success for rare-disease drug development and launch; patient and drug safety; and quality and compliance excellence.
- Mitsuhiro Henry Umebayashi, Partner, Strategy & Organization Practice, Singapore. Henry leads the S&O practice in South-East Asia and supports clients from multiple industries, such as consumer goods, energy & utilities, infrastructure and healthcare. His main focus is supporting clients with business transformation and growth acceleration arising from management challenges such as sustainability, globalization and digitalization.
- Arjun Vir Singh, Partner, Financial Services Practice, Dubai. Arjun joined ADL in 2020 as the Head of Financial Services for the Middle East region. Actively engaged with fintech, payments, and digital banking, as well as the wider start-up ecosystem across the Middle East region and beyond, Arjun has deep sectorial knowledge. He has launched and managed a payments and fintech business for a large conglomerate across multiple markets in the Middle East and SEA region.
Ignacio Garcia Alves, Chairman and Chief Executive Officer of Arthur D. Little , comments: “I would like to congratulate our nine new Partners, who have worked hard and smart to become true entrepreneurs. Each promotion is richly deserved, and we are extremely grateful for the role they have played in the firm. At ADL we place tremendous value on our people. These nine colleagues have shown they are ready for the next step of their careers, and we are truly excited as they enter into their era of partnership.”
About Arthur D. Little
Arthur D. Little has been at the forefront of innovation since 1886. We are an acknowledged thought leader in linking strategy, innovation and transformation in technology-intensive and converging industries. We navigate our clients through changing business ecosystems to uncover new growth opportunities. We enable our clients to build innovation capabilities and transform their organizations.
Our consultants have strong practical industry experience combined with excellent knowledge of key trends and dynamics. ADL is present in the most important business centers around the world. We are proud to serve most of the Fortune 1000 companies, in addition to other leading firms and public sector organizations.
For further information, please visit www.adlittle.com or www.adl.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220315005634/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release
- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release
With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp
Cessna Grand Caravan EX to Feature New Executive Interior Options, Expanding Opportunities for Elevated Missions15.7.2025 18:05:00 CEST | Press release
The legendary Cessna Grand Caravan EX will now feature three new executive interior schemes for customers to select when designing their aircraft cabin. The Lunar, Obsidian and Saddle Sport interiors join the existing Canyon and Savanna schemes, providing a broader range of standard choices. The new interior options are available to customers starting this month and allow them to further tailor the interior of their aircraft based on their personal preference or mission. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715021096/en/ Cessna Grand Caravan EX to feature new executive interior options, expanding opportunities for elevated missions (Photo Credit: Textron Aviation) The Cessna Grand Caravan EX is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. Premium versions of each of the new interiors are also available, featuring quilted seat stitching and plush carpet, providing an elev
7 Million Tokens Sells Out in less than One Hour—$MBG Token Pre-Sale Shatters Expectations15.7.2025 17:27:00 CEST | Press release
MultiBank Group, the world’s largest and most regulated financial derivatives institution, has set a new benchmark in digital asset launches. The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715055611/en/ The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. Commenting on the success of the Pre-Sale, Naser Taher, Founder and Chairman of MultiBank Group, said: “The sell-out of our initial $MBG Token offering in less than one hour is a decisive validation of our vision. In a market saturated with speculation, the response we received confirms that institutional-grade transparency, regulatory integrity, and asset-backed value are what investors are now demanding. $MBG is here for the long term, reflecting t
First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test15.7.2025 17:01:00 CEST | Press release
Study addressing feasibility of using multi-cancer detection tests in future trials aims to enroll up to 24,000 participantsShield MCD reviewed by FDA as part of NCI’s investigational device exemption (IDE) Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute (NCI)’s Vanguard Study to evaluate emerging multi-cancer detection (MCD) technology. Guardant’s Shield™ MCD test was selected for use in the four-year study, which aims to enroll up to 24,000 patients and evaluate the use of MCD tests—blood tests that can screen for several types of cancer simultaneously—in future randomized controlled trials. Guardant’s Shield MCD test was chosen for the study based on the overall performance of its Shield platform in detecting 10 cancer types, including lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver and gastric. The data were presented at the 2025 American
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom